Tenax Therapeutics, INC Form 4 insider transactions

Declan Doogan, a Director of Tenax Therapeutics, Inc., purchased 53,000 shares of common stock on September 16, 2026 for $1.92 per share.

Christopher Thomas Giordano, CEO and a Director of Tenax Therapeutics, Inc., purchased 10,850 shares of common stock on September 11, 2026.

Thomas R Staab Ii, Chief Financial Officer of Tenax Therapeutics, Inc., purchased 5,675 shares of common stock on September 11, 2026 for $1.94 per share.

ADAR1 Capital Management, LLC and 1 other reported changes in beneficial ownership of Tenax Therapeutics, Inc. common stock on September 3, 2026.

ADAR1 Capital Management, LLC and 1 other reported changes in beneficial ownership of Tenax Therapeutics, Inc. common stock on August 31, 2026.

ADAR1 Capital Management, LLC and 1 other reported changes in beneficial ownership of Tenax Therapeutics, Inc. common stock on August 20, 2026.

Christopher Thomas Giordano, CEO and a Director of Tenax Therapeutics, Inc., reported multiple transactions in common stock on July 13, 2026.

Tenax Therapeutics CFO Thomas R. Staab II was granted 10,000 restricted shares and 450,000 stock options.

Tenax Therapeutics' Interim CFO, Thomas McGauley, was granted 50,000 stock options with a future vesting schedule.

TENAX Therapeutics Director Michael H. Davidson filed a Form 4 detailing his beneficial ownership of common stock and various derivative securities, including new stock options and warrants.

TENAX THERAPEUTICS CEO Christopher Thomas Giordano filed a Form 4 detailing his beneficial ownership of common stock and various stock options.

TENAX THERAPEUTICS, INC. Chief Medical Officer Stuart Rich reported the acquisition of 250,000 new stock options with an exercise price of $13.30, alongside other option grants and existing holdings.

Gerald T. Proehl, a Director and 10% owner of Tenax Therapeutics, Inc., reported the acquisition of 3,000 stock options and updated his beneficial ownership.

TENAX THERAPEUTICS, INC. Director June Sherie Almenoff reported the acquisition of 30,000 stock options with an exercise price of $13.3, exercisable from January 9, 2027.

TENAX THERAPEUTICS, INC. Director Declan Doogan reported the acquisition of 30,000 stock options and beneficial ownership of 2,274 common shares.

TENAX Therapeutics Director Robyn Hunter reported the acquisition of 30,000 stock options, signaling potential confidence in the company's future.

TENAX Therapeutics' Chief Medical Officer and Director, Stuart Rich, increased his direct and indirect holdings of common stock through recent open market purchases.

TENAX THERAPEUTICS' Chief Medical Officer, Stuart Rich, increased his direct and indirect holdings of common stock and holds significant stock options.

TENAX Therapeutics CEO Christopher Thomas Giordano acquired additional common stock in open market purchases over three days in November 2025, increasing his direct beneficial ownership.

A Tenax Therapeutics director amended a Form 4 filing to correct the ownership form of 1,993 shares acquired indirectly through Meadowlark Management, LLC.

TENAX Therapeutics' Interim CFO, Thomas McGauley, acquired 8,000 shares of common stock across direct and indirect holdings on November 17, 2025.

A director at Tenax Therapeutics, June Sherie Almenoff, increased her direct beneficial ownership of common stock through open market purchases.

Tenax Therapeutics director June Sherie Almenoff acquired 80,000 stock options with an exercise price of $5.75, effective July 1, 2025, increasing her total beneficial ownership of derivative securities to 180,008 options.

TENAX THERAPEUTICS Director Michael H. Davidson filed a Form 4, disclosing the acquisition of 80,000 stock options and detailing existing holdings of common stock, pre-funded warrants, and additional stock options.

Tenax Therapeutics, Inc. Director Declan Doogan reported the acquisition of 80,000 stock options with an exercise price of $5.75, effective July 1, 2025, as part of changes in his beneficial ownership.

TENAX THERAPEUTICS, INC. Director Gerald T. Proehl reported the acquisition of 80,000 new stock options and updated his beneficial ownership of common stock and various derivative securities, including warrants tied to the Phase 3 LEVEL Study data.

TENAX THERAPEUTICS, INC. Director Robyn Hunter reported the acquisition of 80,000 stock options with an exercise price of $5.75, exercisable from July 1, 2026, and expiring on July 1, 2035.

Stuart Rich, Chief Medical Officer of Tenax Therapeutics, reports the acquisition of stock options and changes in beneficial ownership of common stock.

Tenax Therapeutics CEO Christopher Thomas Giordano was granted stock options for 1,400,000 shares on May 16, 2025, according to a Form 4 filing.

Dellora Investments LP reports a decrease in its holdings of Tenax Therapeutics, Inc., resulting in the firm no longer being a 10% shareholder.